2.58
-1.15%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 3D Medicines
Its shares trade on HKEX under the ticker 1244.HK. It has been listed since 15 December 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥356.1m and a net loss of CN¥177.5m. At that date it held total assets of CN¥936.6m and shareholders' equity of CN¥597.0m.
3D Medicines, Inc. is an investing holding company, which focuses on the development and commercialization of immuno-oncology (I/O) therapies with differentiated clinical benefit in response to the trend of treating cancer as a chronic disease. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-12-15. The firm focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The firm has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The firm's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The firm also has a number of innovative drug research and development pipelines. The firm primarily operates in the domestic Chinese market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Dec 2022
- Employees
- 215
- Website
- 3d-medicines.com ↗
Leadership
Pay as last reported
- Mr. Zhaolong GongExecutive Chairman of the Board, Chief Executive Officer, since 2018
- Ms. Jing ZhangChief Financial Officer
- Mr. Yue HeSenior Director - Quality Management
- Mr. Gan DingChief Commercial Officer
- Mr. Yihui LinHead - Translational Medical Center
- Mr. Shen XiaoChief Strategy Officer, Chief Medical Officer
- Ms. Ching Yi LiJoint Company Secretary
- Ms. Fang XiaJoint Company Secretary
- Ms. Yawen ChenNon-Executive Director
- Mr. Feng ZhouNon-Executive Director
- Mr. Pai ZhuNon-Executive Director
- Mr. Jin LiNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 3D Medicines Inc operates in the Health Care sector with a focus on Biotechnology.
- The company has a first marketed drug, Envafolimab, a subcutaneously injected PD-L1 inhibitor for pan-tumor treatment.
- 3D Medicines Inc has built a complete set of internal R&D systems covering drug discovery to registration.
Weaknesses
- 3D Medicines Inc is headquartered in Shanghai, China, limiting its international market reach.
- The company primarily operates in the domestic Chinese market, which restricts its global expansion.
- 3D Medicines Inc has only one marketed drug, Envafolimab, with limited product diversity.
Opportunities
- The company's focus on immuno-oncology therapies aligns with the trend of treating cancer as a chronic disease.
- 3D Medicines Inc's R&D pipeline offers potential for new drug discoveries in cancer chronic disease treatment.
- The firm's internal R&D systems can support further innovation in cancer pain management.
Threats
- The biotechnology industry faces intense competition from other firms in the Health Care sector.
- Regulatory challenges in the Chinese market may impact the commercialization of new drugs.
- The company's reliance on a single marketed drug, Envafolimab, poses a risk if market demand shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.